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Glasgow, Glasgow, G61 1QH, UK and 4Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee,
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Background: Proteomics-based approaches for biomarker discovery are promising strategies used in cancer research. We present
state-of-art label-free quantitative proteomics method to assess proteome of renal cell carcinoma (RCC) compared with noncancer
renal tissues.
Methods: Fresh frozen tissue samples from eight primary RCC lesions and autologous adjacent normal renal tissues were
obtained from surgically resected tumour-bearing kidneys. Proteins were extracted by complete solubilisation of tissues using
filter-aided sample preparation (FASP) method. Trypsin digested proteins were analysed using quantitative label-free proteomics
approach followed by data interpretation and pathways analysis.
Results: A total of 1761 proteins were identified and quantified with high confidence (MASCOT ion score threshold of 35 and
P-value o0.05). Of these, 596 proteins were identified as differentially expressed between cancer and noncancer tissues. Two
upregulated proteins in tumour samples (adipose differentiation-related protein and Coronin 1A) were further validated by
immunohistochemistry. Pathway analysis using IPA, KOBAS 2.0, DAVID functional annotation and FLink tools showed enrichment
of many cancer-related biological processes and pathways such as oxidative phosphorylation, glycolysis and amino acid synthetic
pathways.
Conclusions: Our study identified a number of differentially expressed proteins and pathways using label-free proteomics
approach in RCC compared with normal tissue samples. Two proteins validated in this study are the focus of on-going research in
a large cohort of patients.
Renal cell carcinoma (RCC) is a heterogeneous disease and its
incidence has been increasing over the past 20 years (Drucker,
2005). It is the most common (490%) kidney cancer and accounts
for 2–3% of all adult malignancies (Rini and Atkins, 2009).
Worldwide, there were B209 000 new cases of RCC diagnosed
with corresponding 102 000 RCC-specific deaths in 2006 (Gupta
et al, 2008). Every year,B4000 people die in the United Kingdom
because of RCC. Renal cell carcinoma is often asymptomatic; the
onset of symptoms such as haematuria and abdominal pain
usually, but not always, indicate advanced disease. A third of cases,
however, are metastatic at the time of their initial diagnosis (Weiss
and Lin, 2006) and 30% of the patients develop metastatic disease
following surgical extirpation of clinically localised disease
(Campbell et al, 2003; Janzen et al, 2003).
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Management of metastatic disease (450% of RCC disease) is a
real clinical challenge. Previous systemic treatment for metastatic
disease with interleukin-2 and interferon-a was associated with
modest survival benefit at best (Pyrhonen et al, 1999). Significant
research, however, aimed at identification of abnormal signal
transduction in RCC has provided insights into therapeutic
molecular targets (Najjar and Rini, 2012) and pathways – the
mTOR signalling pathway and the hypoxia-inducible pathway
being the two main pathways involved in clear cell RCC. The clear
cell histology is the most common subtype of RCC (Escudier et al,
2012). Targeted therapies developed in the recent years for
metastatic disease inhibit tyrosine kinase (sunitinib, axitinib,
pazopanib and sorafenib), vascular endothelial growth factor
(VEGF) (bevacizumab) and mTOR (temsirolimus and everolimus)
(Singer et al, 2013). Nevertheless, for the locally advanced RCC,
there is no approved adjuvant therapy in place. Even with the
recent advances in chemotherapy, durable and complete recovery
remains elusive.
Given the enormity of the unmet clinical needs, research is
needed to uncover the molecular basis of RCC. Even with the
speedy progress in understanding cancer biology in general, the
primary events leading to RCC remain unclear. Recent advances in
high-throughput technologies have enabled us to analyse system-
wide changes simultaneously and these advancements have been
successfully used to understand molecular mechanisms and to
identify biochemical markers of diseases. Although microarrays
allow quantification of gene expression, studying at protein level
remains a complementary method (Lichtenfels et al, 2009).
Moreover, studying at protein level is desirable as mRNA levels
do not always correlate well with the protein abundances.
Proteomics-based approaches allow analyses not only at transla-
tional levels (Lichtenfels et al, 2009), but also at complex post-
translational levels (Walther and Mann, 2010). Early in 2001, Sarto
et al (2001) reviewed the application of two-dimensional electro-
phoresis-based proteomics in RCC and discussed the role of
mitochondrial enzyme manganese superoxide dismutase in the
regulatory functions of cells. In 2003, Seliger et al (2003) reviewed
the progress in identifying RCC-associated biomarkers using
proteomics and transcriptomics approaches and compared the
complementarity between these two ‘omics’ technologies. Their
review showed a considerable number of proteins differentially
expressed in RCC compared with healthy tissue: overexpression of
manganese superoxide dismutase, heat shock protein 27, cyto-
keratin 8, stathmin and vimentin, and underexpression of ubiquitinol
cytochrome C reductase, NADH-ubiquinone oxidoreductase com-
plex 1 and isoforms of the plasma glutathione peroxidase in RCC.
Recently, Masui et al (2013) used isobaric tags for relative and
absolute quantitation (iTRAQ) proteomics method to compare
protein expression profiles of metastatic and localised RCC and
identified 29 proteins differentially expressed (12 overexpressed
and 17 underexpressed in metastatic RCC) between them. Higher
expressions of profilin-1, 14-3-3 z/d and galectin-1 proteins were
found in metastatic RCC in their study and correlated with poor
prognosis. Perroud et al (2009) carried out liquid chromatography-
tandem mass spectrometry (LC-MS/MS)-based proteomics study
on 50 FFPE samples (normal kidney and clear cell renal cancer).
This study identified and quantified 777 proteins, of which 105
were differentially, expressed between Fuhrman grades 1–4 clear
cell kidney cancer and normal kidney tissues. Further analysis
showed grade-dependent alteration in glycolytic and amino acid
synthetic pathways, in addition to proteins in acute phase and
xenobiotic metabolism signalling.
Quantitative proteomics has been used to identify and quantify
proteins in complex biological samples (Wang et al, 2008). The
classical method for quantitative analysis of protein mixtures is by
protein separation and comparison by two-dimensional poly-
acrylamide gel electrophoresis (2D-PAGE), followed by MS or MS/MS
(Balabanov et al, 2001; Shi et al, 2004). However, 2D-PAGE
technique suffers from its inability to analyse hydrophobic, very
high or low molecular weight proteins (Wang et al, 2008).
Moreover, this technique remains a labour-intensive approach,
requiring several different experiments for high-throughput
studies.
To address this, non-gel-based quantitative proteomics methods
have been developed to widen the protein dynamic range and
profile (Wang et al, 2008; Zhu et al, 2010). These approaches utilise
isotope-labelled compounds that are identical to the properties of
their natural compounds except in mass that allows for their
identification in mass spectrometry. Stable labelling approaches
deployed include isotope-coded affinity tag (ICAT), stable isotope
labelling by amino acids in cell culture (SILAC), iTRAQ, 15N/14N
metabolic labelling and other chemical labelling (Chen and Yates,
2007; Veenstra, 2007). These approaches are coupled to LC for
separation before MS or MS/MS identification. Some limitations of
the above approaches include increased sample preparation time,
more complex methodology and higher costs attributed to labelling
reagents (Wang et al, 2008). Furthermore, simultaneous quantifi-
cation using labelling methods is only possible between few
samples (Wang et al, 2008; Zhu et al, 2010). Label-free
quantification is an alternate to often costly labelling strategies in
complex samples like cancer tissues. The use of this approach has
increased enormously in the past 10 years and has shown potential
for identification and quantification of differentially expressed
proteins in normal and diseased samples. The strategy of using
label-free method in complex samples has the potential as a
screening tool in biomarker discovery.
Here, we describe use of label-free MS to compare protein
expression in RCC vs noncancer renal tissue from the same
tumour-bearing kidneys. The major objectives were to discover
differentially expressed proteins between RCC and noncancer renal
tissues in order to infer altered signalling and metabolic pathways
in RCC.
MATERIALS AND METHODS
Tayside Urological Cancer Network (TUCAN), Dundee, Scotland
in collaboration with Tayside Tissue Bank, Dundee, Scotland has
established a large bio-repository of resected renal cancer tissues
with prior ethical approval (approval number 12/ES/0083). Using a
validated protocol, renal tissue samples were prospectively
collected from patients undergoing nephron-sparing or radical
nephrectomy. From the same kidney specimen, two samples were
collected: one from healthy renal tissue (noncancer tissue) and
another from renal cancer (cancer tissue). In total, the study had
eight pairs of tissues, providing 16 samples for further processing.
Label-free quantitative proteomics approach of the present study
included four basic steps: (1) sample preparation – protein
extraction, reduction alkylation and digestion; (2) sample separa-
tion by LC and analysis by MS/MS; (3) data analyses – peak
picking, ion abundance quantification, peptide and protein
identification, quantification and statistical analyses; and (4) data
interpretation and pathway analysis.
Protein extraction, reduction, alkylation and digestion. None of
the participants received neoadjuvant chemotherapy, immuno-
therapy or radiotherapy. The tissue samples were washed with
normal saline and stored at  70 1C following surgery. Before
processing, samples were cut on dry ice to give approximate
weights between 15 and 25mg. Individual samples were soaked in
300 ml of butanol and heated at 95 1C for 5min to remove lipids
(modification of protocol for this study). During standardisation,
filter-aided sample preparation (FASP) method without prior
butanol treatment using fresh frozen tissues did not yield enough
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proteins. This was thought to be because of the presence of lipids
known to significantly reduce protein extraction. Further
development of the method included soaking and heating the
samples in butanol and centrifugation to recover proteins for
further processing. This standardised approach was then adopted
in our study to overcome the interference from lipids in nanoLC-
MS analysis. Proteins were recovered as pellets after centrifuga-
tion at 13 000 g, and were completely solubilised in sodium
dodecyl sulphate and digested in solution with trypsin using the
FASP method (Wisniewski et al, 2009).
Sample separation by LC and analysis by MS/MS. Following
FASP digestion, peptides from the samples were quantified using
NanoVue spectrophotometer (GE Healthcare, Hertfordshire, UK)
and normalised before LC/MS analysis. Analysis of peptides was
performed on a Velos orbitrap (Thermo Scientific, Bremen,
Germany) mass spectrometer coupled with a Dionex Ultimate
3000 RS (Thermo Scientific). The following LC buffers were used:
buffer A (2% acetonitrile and 0.1% formic acid in Milli-Q
water (Merck, Darmstadt, Germany) (v/v)) and buffer B (80%
acetonitrile and 0.08% formic acid in Milli-Q water (v/v)).
Aliquots of 2 ml of each sample were loaded at 5 ml min 1 onto a
trap column (100 mm 2 cm, PepMap nanoViper C18 column,
5 mm, 100 Å, Thermo Scientific) and equilibrated in 98% buffer A.
The trap column was washed for 3min at the same flow rate and
then the trap column was switched in-line with a Thermo
Scientific, resolving C18 column (75 mm 15 cm, PepMap RSLC
C18 column, 2 mm, 100 Å). The peptides were eluted from the
column at a constant flow rate of 300 nlmin 1 with a linear
gradient from 98% buffer A to 40% buffer B in 90min and then to
90% buffer B by 92min. The column was then washed with
98% buffer B for 10min and reequilibrated in 98% buffer A for
24min. LTQ-Orbitap Velos (Thermo Scientific) was used in data-
dependent mode. A scan cycle comprised MS1 scan (m/z range
from 335 to 1800) in the velos orbitrap followed by 10 sequential-
dependant MS2 scans (the threshold value was set at 5000 and the
minimum injection time was set at 200ms) in LTQ with collision-
induced dissociation. The resolution of the Orbitrap Velos was set
at to 60 000. To ensure mass accuracy, the mass spectrometer was
calibrated on the first day that the runs were performed. To
monitor MS performance throughout the analysis, a QC sample
consisting of 100 fmole of 6 bovine proteins digest (ARC Sciences,
Hampshire, UK) was run between every 10 samples. The samples
were randomised and ran in triplicate.
Abundance quantification. In total, 48 samples (8 specimens 2;
cancer and noncancer;  3 technical replicates) were analysed in
nanoLC-MS. The raw LC-MS/MS data were imported into
Progenesis LC-MS (version 4.0, Nonlinear Dynamics Limited,
Newcastle upon Tyne, UK) software and the ion intensity maps for
all the 48 sample runs were examined visually for defects. There
were no detectable defects in any of the runs and all the 48 samples
were included in the analysis. Based on visual examination, total
number of peaks and total intensity, one of the samples was
selected as reference and all other ion intensity maps from rest of
the samples were aligned to it using the ‘Automatic Alignment’
function in the software. After all the runs were aligned with the
reference, peptide ions (features) with charge state over 5 were
considered unreliable and were filtered out and removed. Ion
abundance quantifications were computed from the peak volumes
of the ion chromatograms using protein correlation profiling
method (Schulze and Usadel, 2010). Protein abundances were
calculated from the sum of all normalised unique peptide ion
abundances for a specific protein on each run.
Peptide/protein identification. We used MASCOT protein
search engine (www.matrixscience.com – local installation on the
server) to identify the peptides in the MS/MS spectra. To improve
the quality of the spectral data being used in the search, MS/MS
spectra of the top three ‘ranks’ for each feature were exported to
MASCOT search engine. Using the peptide score distribution from
the MASCOT search results, ion score threshold of 35 (corres-
ponding to P-valueo0.05) was arrived and the identified peptides
with ion scores of o35 were discarded. The filtered MASCOT
search results were imported back into the Progenesis LC-MS and
conflicts for peptide assignments at protein level were examined
case by case and resolved appropriately. Only the proteins with at
least two uniquely identified peptides were retained for further
analysis.
Statistical analysis. To explore the patterns in the protein
quantification data and to highlight the similarities and
differences between the cancer and noncancer groups, we
performed principal component analysis (in R language) and
plotted the first three principal components using RGL package.
We also performed hierarchical clustering using correlation as a
distance metric on the protein quantification data in Progenesis
LC-MS. In addition, we performed hierarchical clustering analysis
using pvclust package in R (http://cran.r-project.org). To examine
the differences in protein abundances between cancer and
noncancer tissues, we performed analysis of variance (ANOVA)
test between the cancer and noncancer tissue groups in
Progenesis LC-MS. In addition, the protein abundance data were
analysed in R–Bioconductor using ‘limma’ package to identify
differentially expressed proteins between these two groups.
Pathways analysis. As we were interested in the signalling
networks and metabolic pathways enriched in the differentially
expressed proteins, we analysed these using three different publically
available pathways enrichment tools that use well-established
databases. As these tools would not recognise some of the protein
IDs, the protein identifiers (UniProtKB AC/ID, UniRef100 and IPI)
were mapped to Entrez Gene IDs posting the data to UniProt
(EMBL-EBI, Cambridge, UK; SIB, Geneva, Switzerland; PIR,
Washington, DC, USA) Knowledgebase using a Perl script. The
mapped Entrez Gene IDs from the differential expression analyses
were used to identify enriched pathways and diseases in KOBAS 2.0
online tool (Xie et al, 2011), DAVID functional annotation tool
(Huang da et al, 2009) and FLink(frequency-weighted links tool;
http://www.ncbi.nlm.nih.gov/Structure/flink/flink.cgi). In addition,
the differentially expressed proteins were analysed using IPA (Build
version: 212183, Release date: 05-02-2013, Ingenuity Systems,
www.ingenuity.com).
Immunohistochemical analysis. Among the identified proteins,
we chose to validate two proteins that have been reported to be of
prognostic significance in renal or any other cancers and have
commercially available antibodies. However, validation of all other
remaining proteins using immunohistochemistry is in progress.
Immunohistochemical staining on tissue sections of the eight
patients with renal cancer and noncancer tissue was performed as
described previously (King et al, 2012). Antigen retrieval and
deparaffinisation was performed using DAKO (Cambridge, UK)
EnVision FLEX Target Retrieval solution (high pH) buffer in a
DAKO PT Link. Immunostaining using DAKO EnVision FLEX
system on a DAKO Autostainer Link 48 was carried out according
to the manufacturer’s protocol. Sections were incubated with
primary antibodies specific for Coronin 1A (US Biological, Salem,
MA, USA) and adipose differentiation-related protein (ADFP;
Abcam, Cambridge, UK) for 30min. The DAKO substrate working
solution was used as a chromogenic agent for 2 5min and
sections were counterstained in EnVision FLEX haematoxylin.
Sections known to stain positively were included in each batch and
negative controls were prepared by replacing the primary antibody
with DAKO antibody diluents. Results were scored by an
experienced renal pathologist as diffuse or focal staining.
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RESULTS
The demographic details of the participants are shown in Table 1.
Peptide extracts were randomised and analysed in triplicate by
nanoLC-MS on a velos orbitrap. To account for technical
variations and to strengthen the quality of the data, we aliquoted
3 technical replicates from each specimen that gave us a total of 48
nanoLC-MS runs. Using the workflow described in the methods,
65 753 spectra were used in the MASCOT search that identified
17 804 peptides (Po0.05, minimum ion 2). From the identified
peptides, 1761 proteins showing at least two unique peptides per
protein were identified and quantified.
To explore the global protein expression patterns in RCC and
noncancerous renal tissues, principal component analysis was
performed. The first three principal components (PCs) captured
57.31, 11.5 and 6.6 percentages, respectively, of the total variance in
the data set. Figure 1 shows complete separation of cancer and
noncancer tissue groups by both PC1 and PC2, indicating a clear
difference in protein expression between the two groups. Convin-
cingly, all the three technical replicates from the same specimens
are tightly grouped, giving us confidence on our study. The plots
show possible existence of well-defined differences between the
protein abundances of cancer and noncancer samples at the global
level. To show the general pattern of proteome in cancer and
noncancer samples in the data set, we have drawn an arbitrary
diagonal line in the PCA plot (Figure 1). In this figure all three
replicates of samples GN4082-tumour and 4614-normal have
almost similar PC1 values, although they are very well separated by
PC2. Furthermore, when we compare the individual specimens
with their matching cancer and noncancer tissues, GN4082 tumour
vs GN4082 normal and 4614 tumour vs 4614 normal, it is
convincing that the cancer and noncancer samples are very well
separated chiefly on the basis of PC1, giving confidence in the
overall pattern. Hierarchical clustering of the protein quantification
data also showed separation of the samples belonging to cancer
and noncancer groups (Supplementary Data).
To identify the proteins that were expressed differentially
between the RCC and noncancer tissues, ANOVA test was
performed in Progenesis LC-MS that identified 558 proteins
(Po0.05 and fold change over as differentially expressed between
the cancer and noncancer groups). In addition, to increase our
confidence on differential expression analysis and to correct for
multiple testing (not available in Progenesis LC-MS), we used
linear modelling to identify differentially expressed proteins. Using
FDR-adjusted Po0.05 and log2 fold change over 1.0 (linear scale
fold change over 2) as cutoff, 596 proteins were identified from the
linear modelling analysis as differentially expressed between the
cancer and noncancer groups (Supplementary Table 1). Tables 2
and 3 show the top 25 (ranked by fold change with significant
FDR-adjusted P-value) upregulated and downregulated proteins in
RCC respectively. Some of the upregulated proteins in cancerous
tissues include thymidine phosphorylase, annexin A4, periostin,
aggrecan core protein, serpin H1, ADFP, 6-phosphofructokinase
type C, Coronin 1A, von Willebrand factor, integrin-b, tyrosine-
protein kinase receptor and sialic acid synthase. Proteins down-
regulated in cancerous tissue include synaptopodin 2, ubiquitin
carboxyl-terminal hydrolase isozyme L1, L-xylulose reductase,
cadherin-16, fructose-bisphosphate aldolase B, uromodulin and
NADH dehydrogenase (ubiquinone).
We used three publically available pathways analysis tools
(webservers), namely, KOBAS 2.0, DAVID and FLink, for finding
enriched pathways in the 596 differentially expressed proteins. The
KOBAS 2.0 webserver uses KEGG Pathway, BioCyc, Reactome,
Pathway Interaction Database and Panther databases to identify
statistically enriched pathways in the differentially expressed
proteins (Entrez Gene IDs), against the background of all the genes
in the human genome. The important enriched pathways include
oxidative phosphorylation, TCA cycle, peroxisome proliferator-
activated receptor (PPAR) signalling pathway and integrin signalling
pathway (Table 4). The DAVID functional annotation tool uses over
40 annotation categories incorporating many databases including
Gene Ontology, protein–protein interactions, protein functional
domains and pathway databases and finds enriched terms similar to
KOBAS 2.0. The results from the DAVID functional annotation
chart are given in Supplementary Table 1. The FLink uses a subset of
Entrez databases to rank enriched terms using ‘frequency-weight’
method, and the top enriched terms ranked by percentage coverage
are given in Supplementary Table 2. We also used IPA for analysing
the differentially expressed proteins. Mitochondrial dysfunction,
LPS/IL-1-modulated inhibition of RXR and LXR/RXR are the top
enriched pathways in IPA analysis (Figure 2A). The IPA network
analysis showed important upstream regulators and downstream
effectors involved in carcinogenesis such as PGR, PPARA, TNF,
RXRA, p53, PPARGC-1-a, SMAD3 and CTNNB1 at the centre of
the merged networks (Figure 2B). However, these data and
confirmation of their involvement in carcinogenesis need further
studies by western blot and/or immunohistochemistry.
Validation of proteins that are overexpressed in renal cancer but
not in normal renal tissue. Given the large number of proteins
differentially expressed in tumour and normal tissues as demon-
strated by the results, we chose to use immunohistochemistry to
validate two of the proteins that were upregulated in tumour
samples. These include Coronin 1A and ADFP. The choice was
based on the reports of these two proteins involved in key
pathways of kidney or any other cancers in the literature as
suggested in the Materials and Methods. Coronin 1A is an actin
remodelling protein that has been reported to be overexpressed in
breast cancer (Kim et al, 2009a; Klopfleisch et al, 2010). Our
immunohistochemical results revealed that Coronin 1A is not
expressed by the cells of the primary renal cancer (Figure 3A), but
Table 1. Demographic characteristics of the study cohort and tumour features
Sr. no.
Age
(years) Sex
Tumour size
(mm) Histopathology type Surgery Stage
Furhman
grade
1 78 Male 55 Clear cell carcinoma Nephrectomy T3bN0MO 2
2 66 Female 65 Clear cell carcinoma Nephrectomy T3bN0MO 3
3 68 Female 55 Clear cell carcinoma Nephrectomy T1bN0MO 2
4 67 Female 3 Clear cell carcinoma Nephrectomy T1aN0MO 3
5 50 Male 115 Clear cell carcinoma Nephrectomy T3aN0MO 3
6 60 Female 46 Clear cell carcinoma Nephrectomy T1bN0MO 2
7 82 Female 82 Clear cell carcinoma Nephrectomy T3bN0MO 3
8 74 Male 54 Clear cell carcinoma Nephrectomy T3bN0MO 4
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was highly expressed in the infiltrating lymphocytes in all the eight
renal cancer specimens. The ADFP is a major lipid droplet protein
present in all cells that accumulate lipids either normally or
abnormally. It was expressed in the cytoplasm-surrounding lipid
droplets within the renal cancer cells (Figure 3B). The staining was
seen in the majority of the tumour cells in all the cases.
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Figure 1. Principal component analysis of global protein profiles in cancer and noncancer renal tissues. The plot shows principal component
1 (PC1) on X axis and principal component 2 (PC2) on Y axis, and they capture 57.31% and 11.5%, respectively, of the total variance. Blue data
points denote noncancer renal tissues and red data points denote RCC tissues. The data points are marked with the sample identifiers (specimen
number, noncancer/tumour tissue and technical replicate 1/2/3). An arbitrary diagonal line was drawn across the plot to show the separation
of cancer and noncancer tissues. A full colour version of this figure is available at the British Journal of Cancer journal online.
Table 2. Top upregulated proteins in cancerous tissues compared with the normal renal parenchyma (ranked by fold change)
Sr. no. Protein name Protein ID
Fold change
(log2) cancer
vs noncancer P-value
FDR-adjusted
P-value
1 Integrin b tr|B4E0R1|B4E0R1_HUMAN 5.918997073 8.05452E 10 2.86278E 09
2 Von Willebrand factor UniRef100_P04275 3.252970919 1.76848E 14 2.59377E 13
3 Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 UniRef100_O14638 3.113004422 1.65797E 08 4.05426E 08
4 Full-length cDNA clone CS0DI085YI08 of placenta of Homo sapiens tr|Q86TV4|Q86TV4_HUMAN 3.011741403 0.023659047 0.024837091
5 ADFP protein tr|Q6FHZ7|Q6FHZ7_HUMAN 2.950019975 1.12143E 11 7.07877E 11
6 Histone H3.1 UniRef100_UPI0001D3410D 2.898432243 1.31146E 09 4.36579E 09
7 Thymidine phosphorylase UniRef100_UPI0000E571B6 2.888733547 1.32789E 19 4.4794E 18
8 Aggrecan core protein tr|E7EX88|E7EX88_HUMAN 2.745397619 6.5538E 06 9.50207E 06
9 Interferon-g-inducible protein 16, isoform tr|D3DUZ3|D3DUZ3_HUMAN 2.725425564 1.91243E 14 2.76483E 13
10 Coronin 1A IPI00010133 2.717496528 3.83009E 15 6.68285E 14
11 NNMT protein tr|Q6FH49|Q6FH49_HUMAN 2.713371423 1.7417E 09 5.64935E 09
12 cDNA FLJ59379, highly similar to haematopoietic lineage cell-specific protein tr|B4DQ92|B4DQ92_HUMAN 2.65230756 2.87995E 15 5.20448E 14
13 Fatty acid binding protein 7 tr|Q9H047|Q9H047_HUMAN 2.617050396 5.83826E 06 8.56278E 06
14 Periostin tr|B1ALD8|B1ALD8_HUMAN 2.60827884 3.85862E 09 1.15609E 08
15 cDNA FLJ52464, highly similar to GTPase, IMAP family member 4 tr|B4DWA5|B4DWA5_HUMAN 2.527846248 1.22822E 15 2.3452E 14
16 ENO2 protein tr|Q6FHV6|Q6FHV6_HUMAN 2.492047979 1.45322E 10 6.47865E 10
17 Histone H1.5 sp|P16401|H15_HUMAN 2.436089334 3.03607E 16 6.98295E 15
18 Insulin-like growth factor binding protein 7 tr|B4E1N2|B4E1N2_HUMAN 2.418191943 2.65323E 10 1.08269E 09
19 Apoptosis-associated speck-like protein containing a CARD sp|Q9ULZ3|ASC_HUMAN 2.402662738 4.75155E 17 1.20214E 15
20 cDNA FLJ43948 fis, clone TESTI4014924, highly similar to Homo sapiens
cytoplasmic FMR1 interacting protein 1 (CYFIP1), transcript variant 1, mRNA
tr|B3KWV6|B3KWV6_HUMAN 2.331192861 4.53312E 15 7.64586E 14
21 Sialic acid synthase sp|Q9NR45|SIAS_HUMAN 2.23177376 1.29297E 07 2.51631E 07
22 Annexin A4 UniRef100_P09525 2.209750305 8.41075E 13 7.53246E 12
23 6-phosphofructokinase type C UniRef100_Q01813 2.14408679 5.29845E 12 3.69795E 11
24 ATP-dependent RNA helicase DDX1 tr|A3RJH1|A3RJH1_HUMAN 2.137678406 0.000942011 0.001063967
25 Adenosine deaminase tr|F5GWI4|F5GWI4_HUMAN 2.131392334 3.03952E 12 2.27852E 11
Abbreviations: ADFP¼ adipose differentiation-related protein; FDR¼ false discovery rate; NNMT¼nicotinamide N-methyltransferase.
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DISCUSSION
Renal cell carcinoma is the third most common urological
cancer; however, there are limited curative treatment options for
both localised and metastatic diseases. For localised RCC
tumours measuring up to 7 cm, the recommended treatment is
partial nephrectomy (wherever technically possible), with radio
frequency or cryoablative treatments being other alternatives in
small cortical or bilateral tumours. For tumours over 7 cm,
radical nephrectomy is the commonly offered option. Currently,
there is no recommended adjuvant therapy available to treat
locally advanced RCC, although nonspecific immunotherapy
with cytokines IL-2 and/or IFN-a were tried with questionable
benefits in the past. Lack of progress is mainly because of
nonavailability of biomarkers to stratify patients into those who
may or may not benefit from the treatment. Specific immu-
notherapy with tumour vaccines is still under development. For
metastatic disease, targeted therapies with single or combination
of inhibitors of tyrosine kinase, VEGF and mTOR are
recommended. Both specific immunotherapy and targeted
therapies require biomarkers to predict whether such therapy
would be suitable to the patient and actually provide desired
benefits. This underlines the importance of biomarker discovery
in RCC and there is urgent need to discover the following
categories of biomarkers:
1. Early diagnostic biomarkers that could also be used for routine
screening.
2. Therapeutic biomarkers for choosing the right course of
treatment and
3. Prognostic biomarkers for predicting metastatic possibility,
tumour recurrence and treatment outcomes.
High-throughput omics technologies, including proteomics,
have remarkable ability to capture changes in thousands of
variables simultaneously and are found to be useful in biomarker
research. In the present study we used label-free quantitative
proteomics approach for profiling the proteome of resected cancer
and autologous normal kidney tissues. This approach provided a
snapshot of proteins expressed in kidney and also differences in
protein expression between the normal and the diseased tissues. A
total of 1761 proteins showing at least two unique peptides per
protein were identified and quantified. Of these, 596 were found to
be differentially expressed between the cancer and noncancer
groups.
There are several proteomics studies in kidney cancer using
2D-PAGE/MS (Balabanov et al, 2001; Shi et al, 2004; Lichtenfels
et al, 2009; Valera et al, 2010; Giribaldi et al, 2013) and shot gun
proteomics (Perroud et al, 2009). Our method consisting of
complete solubilisation of kidney proteins using FASP followed by
nanoLC-MS has yielded a higher number of proteins compared
with previous studies (Hwa et al, 2005; Okamura et al, 2008;
Table 3. Top down-regulated proteins in cancerous tissues compared with the normal renal parenchyma (ranked by fold change)
Sr. no. Protein name Protein ID
Fold change
(log2) cancer
vs noncancer P-value
FDR-
adjusted
P-value
1 Metallothionein tr|Q8WVB5|Q8WVB5_HUMAN 7.070631065 1.06E 14 1.68E 13
2 Synaptopodin 2 tr|B9EG60|B9EG60_HUMAN 5.063445471 9.29E 12 6.1E 11
3 NADH dehydrogenase (ubiquinone) 1a subcomplex, 8, 19 kDa tr|B1AM93|B1AM93_HUMAN 3.81124236 2.51E 36 2.54E 33
4 Ubiquitin carboxyl-terminal hydrolase isozyme L1 sp|P09936|UCHL1_HUMAN 3.744218547 1.11E 21 4.86E 20
5 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13 kDa (NADH-coenzyme Q
reductase), isoform CRA_a
tr|Q6IBC4|Q6IBC4_HUMAN 3.686259992 3.59E 24 2.02E 22
6 L-xylulose reductase sp|Q7Z4W1|DCXR_HUMAN 3.583275422 4.51E 20 1.57E 18
7 Non-secretory ribonuclease UniRef100_P10153 3.548814593 8.25E 10 2.92E 09
8 NADH dehydrogenase (ubiquinone) iron–sulphur protein 8, mitochondrial (fragment) tr|E9PPW7|E9PPW7_HUMAN 3.432935132 2.5E27 3.17E 25
9 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24 kDa tr|Q6IPW4|Q6IPW4_HUMAN 3.413973508 8.26E 35 4.18E 32
10 Bartter syndrome, infantile, with sensorineural deafness (Barttin) tr|Q5VU50|Q5VU50_HUMAN 3.35833422 3.88E 22 1.78E 20
11 Cadherin-16 UniRef100_O75309 3.349171259 3.13E 27 3.52E 25
12 Calbindin 1, 28 kDa, isoform CRA_b tr|B2R696|B2R696_HUMAN 3.345341765 4.53E 11 2.33E 10
13 Probable N-acetyltransferase 8 sp|Q9UHE5|NAT8_HUMAN 3.334487761 2.4E11 1.36E 10
14 ATPase, Naþ /Kþ transporting, b1 polypeptide, isoform CRA_a tr|A3KLL5|A3KLL5_HUMAN 3.332531661 4.34E 26 4E24
15 Sodium/glucose cotransporter tr|Q8WY15|Q8WY15_HUMAN 3.263975139 9.13E 10 3.18E 09
16 Fructose-bisphosphate aldolase B UniRef100_P05062 3.222229924 2.6E15 4.78E 14
17 NADH dehydrogenase (ubiquinone) 1a subcomplex subunit 2 UniRef100_O43678 3.21030869 7.56E 31 2.55E 28
18 D-b-hydroxybutyrate dehydrogenase, mitochondrial UniRef100_Q02338 3.116941388 7.68E 15 1.23E 13
19 Ubiquinone biosynthesis protein COQ9, mitochondria UniRef100_O75208 3.110815803 1.26E 11 7.81E 11
20 Uromodulin, secreted form tr|E9PEA4|E9PEA4_HUMAN 3.088130282 1.78E 17 4.87E 16
21 cDNA FLJ60317, highly similar to Aminoacylase-1 (EC 3.5.1.14) tr|B4DNW0|B4DNW0_HUMAN 3.066759162 2.07E 18 6.17E 17
22 PDZK1-interacting protein 1 IPI00011858 3.053007695 8.63E 16 1.78E 14
23 NADH dehydrogenase (ubiquinone) iron–sulphur protein 7, mitochondrial tr|F5GXJ1|F5GXJ1_HUMAN 3.048863326 2.46E 30 4.98E 28
24 UDP-glucuronosyltransferase 2B7 UniRef100_P16662 3.046009696 6.41E 09 1.78E 08
25 Glutathione peroxidase 3 UniRef100_P22352 3.037043306 1.02E 13 1.08E 12
Abbreviation: FDR¼ false discovery rate.
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Perroud et al, 2009; Valera et al, 2010; Zhu et al, 2010; Junker et al,
2011). The method in the present study is known to solubilise
membrane and lipid-associated proteins that may explain the large
number of proteins identified. In addition, the number of proteins
differentially expressed between the two groups is higher in our
study. Many of the proteins discovered by other groups (Perroud
et al, 2009; Valera et al, 2010; Giribaldi et al, 2013) are consistent
with the finding reported here. In general, we found our label-free
approach was relatively more comprehensive, rapid and ideal for
analysing large number of clinical samples.
The differences in the abundance of proteins between the RCC
and noncancer renal tissues highlighted important cancer-related
proteins including von Willebrand factor, Ectonucleotide pyro-
phosphatase/phosphodiesterase family member 3, adipose diffe-
rentiation-related protein, Coronin 1A, thymidine phosphorylase,
nicotinamide N-methyltransferase, fatty-acid binding protein 5,
annexin A4, laminin, vimentin, NADH dehydrogenase, metal-
lothionein, ubiquitin carboxyl-terminal hydrolase isozyme L1 and
L-xylulose reductase. These proteins are of particular importance
for a number of reasons:
Ectonucleotide pyrophosphatase/phosphodiesterase family
member 3 (E-NPP3) is overexpressed in RCC (log2 fold
change¼ 3.11, FDR-adjusted P¼ 4.05E 08). E-NPP3 has an
alkaline phosphodiesterase domain and a nucleotide pyro-
phosphatase domain. It cleaves a number of phosphodiester and
phosphosulphate bonds including deoxynucleotides, nucleotide
sugars and NAD. The E-NPP3 has been shown to be upregulated
in invasive bile duct cancers. It has been shown to be a marker for
cell activation in allergic responses (Buhring et al, 2004). Von
Willebrand factor (von Willebrand antigen II) is overexpressed in
RCC (log2 fold change¼ 3.25, FDR-adjusted P¼ 2.59E 13). The
vWF is localised in the extracellular matrix and is involved in cell–
substrate adhesion. It is found to be upregulated in many cancers
of other tissues and linked to tumour angiogenesis (Plate et al,
1993; Zanetta et al, 2000; Franchini et al, 2013), Thymidine
phosphorylase (TP) is overexpressed in RCC (log2 fold
change¼ 2.89, FDR-adjusted P¼ 4.48E 18). It promotes angio-
genesis in vivo and activates growth of endothelial cells in vitro. It
has very high target cell specificity acting only on endothelial cells.
It is implicated in many tumours for its role in tumour
aggressiveness and angiogenesis. The TP targeting has been
suggested for antiangiogenic therapy in tumours (Bronckaers
et al, 2009; Bijnsdorp et al, 2011). Nicotinamide N-methyltransfer-
ase (NNMT) is overexpressed in RCC (log2 fold change¼ 2.71,
FDR-adjusted P¼ 5.65E 09). It is a key enzyme in drug and
xenobiotic compounds metabolism as it catalyses the N-methyla-
tion of nicotinamide and other pyridines. Overexpression of
NNMT in RCC has been widely reported. It has been suggested as
a potential prognostic biomarker in RCC and hepatocellular
carcinoma where its higher expression is linked to poor prognosis
(Kim et al, 2009b; Zhang et al, 2010; D’Andrea et al, 2011). Fatty-
acid binding protein 5 (FABP5) is upregulated (log2 fold
Table 4. Top pathways enriched in the differentially expressed proteins – results from KOBAS 2.0
Sr. no. Pathways Database ID P-value
FDR (Benjamini
and Hochberg)-
corrected P-value
1 Oxidative phosphorylation KEGG PATHWAY hsa00190 0 0
2 Valine, leucine and isoleucine degradation KEGG PATHWAY hsa00280 2.54241E14 3.69497E12
3 Pyruvate metabolism KEGG PATHWAY hsa00620 2.3728E10 2.29897E08
4 Citrate cycle (TCA cycle) KEGG PATHWAY hsa00020 3.09356E10 2.69758E08
5 Propanoate metabolism KEGG PATHWAY hsa00640 8.215E10 5.96957E08
6 Branched-chain amino acid catabolism PID Reactome 500780 8.18667E09 5.49137E07
7 Glycolysis/Gluconeogenesis KEGG PATHWAY hsa00010 4.03624E08 2.514E06
8 Fatty acid metabolism KEGG PATHWAY hsa00071 7.23503E08 3.94309E06
9 ATP synthesis PANTHER P02721 4.77073E07 2.4471E05
10 Respiratory electron transport PID Reactome 500282 2.98826E06 0.000137145
11 Butanoate metabolism KEGG PATHWAY hsa00650 4.85495E06 0.000211676
12 Arginine and proline metabolism KEGG PATHWAY hsa00330 1.15415E05 0.000437574
13 Tryptophan metabolism KEGG PATHWAY hsa00380 1.24063E05 0.00045076
14 Alanine, aspartate and glutamate metabolism KEGG PATHWAY hsa00250 9.2847E05 0.003113944
15 PPAR signalling pathway KEGG PATHWAY hsa03320 0.000113691 0.003540661
16 Glyoxylate and dicarboxylate metabolism KEGG PATHWAY hsa00630 0.000125436 0.003771744
17 Lysine degradation KEGG PATHWAY hsa00310 0.000425581 0.010644352
18 Integrin signalling pathway PANTHER P00034 0.000441775 0.01070076
19 ECM–receptor interaction KEGG PATHWAY hsa04512 0.000637655 0.015027987
20 Pentose and glucuronate interconversions KEGG PATHWAY hsa00040 0.000908772 0.020161889
21 Peroxisome KEGG PATHWAY hsa04146 0.001069004 0.02273588
22 Cytoskeletal regulation by Rho GTPase PANTHER P00016 0.001258049 0.026119495
23 Ascorbate and aldarate metabolism KEGG PATHWAY hsa00053 0.001388723 0.026910372
24 Collecting duct acid secretion KEGG PATHWAY hsa04966 0.001388723 0.026910372
25 Role of mitochondria in apoptotic signalling PID BioCarta 100106 0.002004916 0.038006226
Abbreviations: ATP¼ adenosine triphosphate; ECM¼ extracellular matrix; FDR¼ false discovery rate; PPAR¼peroxisome proliferator-activated receptor; TCA¼ tricarboxylic acid.
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Figure 2. (A) Pathway analysis showing the top enriched canonical pathways. The enrichment of canonical pathways in the differentially
expressed proteins identified by IPA software is shown. The enrichment shows many important pathways that have vital role in tumourigenesis.
(B) Network showing important upstream regulators and downstream effectors in the differentially expressed proteins. Ingenuity Pathway Analysis
showing the interrelationship among some of the differentially expressed proteins including upstream regulators and downstream effectors.
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change¼ 1.7, FDR-adjusted P¼ 1.24E 06) in kidney cancer
tissues. It binds to PPAR-b/d and its overexpression in cancer
tissues, particularly in prostate cancer, has been reported (Morgan
et al, 2010; Tolle et al, 2011).
Coronin 1A, a 57 kDa protein, has been shown to play an
important role in signalling of T lymphocytes (Mugnier et al, 2008)
and is an important member of the coronin family of proteins
(seven members are coded by the mammalian genome). This may
play a crucial role in a number of cytoskeleton-dependant
processes such as cell migration, morphogenesis, cell trafficking
and cytokinesis. A number of human cancers show tumour-
infiltrating lymphocytes (TILs) with known diversity in their
phenotypic expression and function depending on the type of
tumour. The TILs of renal cancers phenotypically differ from the
peripheral blood of the same patients, suggesting an active
interaction between the lymphocytes and tumour cells at the local
level (Kowalczyk et al, 1997). Coronin 1A could be a potential
biomarker to assess the degree of TILs in the renal cancer, but this
needs to be further studied. Coronin 1A was shown to be
significantly correlated with development and migration of breast
cancer cells (Kim et al, 2009a), compared with normal cell lines.
Upregulation of Coronin 1A has been reported by others in RCC
samples (Perroud et al, 2009). Immunostaining showed predomi-
nant expression of this protein in infiltrating lymphocytes rather
than in renal cancer cells. This is an interesting observation, as
RCC is considered as immunogenic malignancy and responds to
immunotherapy. Furthermore, RCCs express common antigenic
determinants that can be recognised by MHC-restricted T
lymphocytes and create a local environment (Schendel and
Gansbacher, 1993; Wang et al, 2008). Bromwich et al (2003)
reported poor correlation between intratumour CD4þ T-lympho-
cyte infiltrates and outcomes of renal cancer following surgical
treatment, and this was independent of the grade of tumour.
Coronin 1A identified in the present study could be used as a
biomarker for quantification of TILs in renal cancer. However,
further work needs to be done to explore the possibility of
measuring this protein in urine and blood as a biomarker for
lymphocytic activation in RCC.
In contrast to Coronin 1A, ADFP has been shown to be
expressed by clear cell carcinoma cells and its expression level has
been reported to correlate with differentiation of cells (Yao et al,
2005). The ADFP, also known as adipophilin, is a member of PAT
B
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family of proteins that have the ability to bind intracellular lipid
droplets. The presence of a large number of lipid droplets and
glycogen granules is a characteristic feature of clear cell RCC
(Yao et al, 2005, 2007; Tickoo and Gopalan, 2008; Urahama et al,
2008). Expression of ADFP has been reported in previous studies
and its expression has shown correlation with the survival of renal
cancer. Moreover, it has been reported that the upregulation of
ADFP is caused by the disruption of VHL/HIF pathway in clear
cell RCC (Yao et al, 2007), and the VHL/HIF pathway is a key
target for the tyrosine-kinase inhibitor therapy in advanced renal
cell carcinoma. The ADFP is overexpressed and secreted in the
urine of patients with RCC and in those with benign kidney
disease, compared with normal healthy adults (Morrissey et al,
2010). There are emerging reports exploring the role of ADFP
measurement in urine as prognostic marker or marker of response
to systemic therapy (Grebe and Erickson, 2010).
Our findings confirm previous reports that ADFP could be a
biomarker for diagnosis, predicting prognosis or response to
treatment (Morrissey et al, 2010). Pathway analysis allowed us to
identify enrichment of various metabolic and signalling pathways,
which are known to play key role in oncogenesis or cancer
progression, from the differentially expressed proteins in this
study. Various pathways such as glycolysis reported previously
(Mathupala et al, 1997; Unwin et al, 2003; Perroud et al, 2006,
2009) were confirmed by our data. The large number of proteins
identified and demonstrated to be differentially expressed in RCC
could be validated by using a larger number of samples and this
may become a part of our future research. The PPAR signalling
pathway, enriched in our study, could be a new potential
therapeutic target in RCC. The transcription factors in PPAR
pathways strongly influence molecular events in cancer cells
(Michalik et al, 2004). The PPARs are nuclear hormone receptors
and exist in three isotopes: a, g and d. They heterodimerise with
another nuclear hormone receptor, retinoid X receptor (RXR), and
exert their effects via regulation of gene transcription upon binding
of ligands (Chinetti et al, 2001). The PPAR/RXR heterodimer exists
in active and inactive forms. In the presence of a ligand, the PPAR
disassociates itself from co-suppressor and becomes active
(Chinetti et al, 2001). The transcription factors in PPAR pathways
strongly influence molecular events in cancer cells (Jackson et al,
2003; Michalik et al, 2004). There are reports that PPAR pathway
activity promotes colonic cell carcinogenesis and has been shown
to be suppressed by nonsteroidal anti-inflammatory drugs.
Similarly, Rho GTPases pathway is dysregulated during hypoxia
in renal cell carcinoma as shown by mRNA levels (Turcotte et al,
2004); Rho A expression is required for HIF-1-a accumulation
during hypoxia, and it could also become a therapeutic target.
Our study also showed a strong evidence of altered mito-
chondrial function as demonstrated by downregulation of a
number of mitochondrial enzymes: fumarate hydratase, succinate
Coronin 1A
Adipose differentiation-related protein (ADFP)
A
B
Kidney cancer
Kidney cancer Normal kidney
Normal kidney tissue
Figure 3. (A) Expression of Coronin 1A in cancerous tissues compared with the corresponding normal kidney tissues. (B) Expression of adipose
differentiation-related protein in cancerous tissues compared with the corresponding normal kidney tissues.
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semialdehyde dehydrogenase, methyl-CoA mutase, agmatinase,
adenylate kinase isoenzyme 4, mitochondrial peptide methionine
sulphoxide reductase, sulphite oxydase, D-b-hydroxybutyrate
dehydronenase, cytochrome C oxydase subunit 4, pyruvate
carboxylase, methylcrotonoyl-CoA carboxylase b-chain and
propionyl-CoA carboxylase a-chain. Indeed, metabolic and
molecular alterations in mitochondria are well documented in
cancers (Modica-Napolitano et al, 2007; Gasparre et al, 2013) and
these alterations are linked to shift in tumour metabolism from
mitochondrial oxidative phosphorylation to aerobic glycolysis (the
Warburg effect), and possible other unknown metabolic pathways
(Vander Heiden et al, 2009) allowing tumour cells to satisfy their
bioenergetic and biosynthetic requirements that are higher than
those of normal cells (Vander Heiden et al, 2009; Zhao et al, 2013).
CONCLUSIONS
Our findings using quantitative label-free proteomics analysis in
RCC revealed a number of differentially expressed proteins with
potential diagnostic and prognostic role as biomarkers in RCC.
The dysregulated pathways identified have a significant potential
for therapeutic targets. The two proteins (Coronin 1A and ADFP)
that were followed up in-depth using immunohistochemistry
show differential expression between cancer and normal renal
parenchymal tissue.
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